基于多替拉韦的二线抗逆转录病毒疗法中多替拉韦耐药性的快速出现。
Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ART.
作者信息
Naidoo Kirusha, Lessells Richard J, Dorward Jienchi, Moosa Mahomed Y S, Sookrajh Yukteshwar, Moodley Pravi, Drain Paul K, Garrett Nigel
机构信息
Department of HIV Vaccines and Pathogenesis, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
出版信息
South Afr J HIV Med. 2025 Apr 23;26(1):1701. doi: 10.4102/sajhivmed.v26i1.1701. eCollection 2025.
The integrase strand transfer inhibitor, dolutegravir (DTG), is widely used in first- and second-line antiretroviral therapy (ART) regimens in South Africa. We describe an adult with virological failure on second-line tenofovir/lamivudine/dolutegravir (TLD2) and rapid emergence of DTG resistance within 3 months, while receiving rifapentine-based tuberculosis preventive therapy.
整合酶链转移抑制剂度鲁特韦（DTG）在南非的一线和二线抗逆转录病毒治疗（ART）方案中被广泛使用。我们描述了一名成年人，其在接受基于利福喷丁的结核病预防性治疗时，二线替诺福韦/拉米夫定/度鲁特韦（TLD2）治疗出现病毒学失败，且在3个月内迅速出现DTG耐药。
Zotero 插件